Objective: Our survey assessed the use of advanced radiotherapy technologies at the designated cancer care hospitals in Japan, and we identified several issues to be addressed. Methods: We collected the data of 397 designated cancer care hospitals, including information on staffing in the department of radiation oncology (e.g. radiation oncologists, medical physicists and radiation therapists), the number of linear accelerators and the implementation of advanced radiotherapy technologies from the Center for Cancer Control and Information Services of the National Cancer Center, Japan. Results: Only 53% prefectural designated cancer care hospitals and 16% regional designated cancer care hospitals have implemented intensity-modulated radiotherapy for head and neck cancers, and 62% prefectural designated cancer care hospitals and 23% regional designated cancer care hospitals use intensity-modulated radiotherapy for prostate cancer. Seventy-four percent prefectural designated cancer care hospitals and 40% regional designated cancer care hospitals employ stereotactic body radiotherapy for lung cancer. Our multivariate analysis of prefectural designated cancer care hospitals which satisfy the institute's qualifications for advanced technologies revealed the number of radiation oncologists (P ¼ 0.01) and that of radiation therapists (P ¼ 0.003) were significantly correlated with the implementation of intensitymodulated radiotherapy for prostate cancer, and the number of radiation oncologists (P ¼ 0.02) was correlated with the implementation of stereotactic body radiotherapy. There was a trend to correlate the number of medical physicists with the implementation of stereotactic body radiotherapy (P ¼ 0.07). Only 175 (51%) regional designated cancer care hospitals satisfy the institute's qualification of stereotactic body radiotherapy and 76 (22%) satisfy that of intensitymodulated radiotherapy. Seventeen percent prefectural designated cancer care hospitals and 13% regional designated cancer care hospitals had a quality assurance committee. Conclusions: The numbers of radiation oncologists and other operating staff might be essential factors in the implementation of advanced radiotherapy technologies. Small proportions of regional designated cancer care hospitals satisfy the institute's qualifications of advanced technologies.
INTRODUCTION
Several advanced radiotherapy technologies have been introduced over the last decade, and their use has contributed to both reductions in the rates of treatment-related complications and improvements in patients' quality of life after cancer treatment (1) (2) (3) . In the USA, the proportion of intensity-modulated radiotherapy (IMRT) used for patients with prostate cancer rose from 28.7% in 2002 to 81.7% in 2005 (4) , and the proportion of IMRT for head and neck cancers rose from 1.3% in 2000 to 46.1% in 2005 (5). Pan et al. (6) conducted a survey on the use of advanced radiotherapy technologies in the USA, and they found that the cumulative adoption of stereotactic body radiotherapy (SBRT) for the treatment of any disease site was ,5% in 2000 versus .60% in 2010. The percentage of physicians using SBRT was 63.9%, but nearly one-half of the physicians reported that they first used SBRT in 2008 or later. IMRT and SBRT have rapidly become widely adopted among American radiation oncologists (ROs).
The Japanese government enacted the Basic Act for Anti-Cancer Measures in June 2006 to promote comprehensive strategies against cancer. The government set basic guidelines and founded a system of designated cancer care hospitals (DCCHs). The prefectural DCCH (P-DCCH) is defined as the coordinating hospital of each prefecture (the 47 prefectures in Japan are akin to the states in the USA), and the regional DCCHs (R-DCCHs) are mainly cardinal hospitals in the secondary medical care area of prefecture. The DCCHs are required to cooperate with each other to deliver comprehensive cancer care, including adequate radiotherapy, surgical treatment, systemic chemotherapy and palliative care to all citizens.
We conducted the present study to survey the current situation regarding the use of novel radiotherapy technologies such as IMRT and SBRT at all of the DCCHs in Japan.
PATIENTS AND METHODS
There are currently two national cancer centers: 51 P-DCCHs and 344 R-DCCHs in Japan (total, 397 DCCHs). We included the two national cancer centers in the grouping of P-DCCHS for a total of 53 hospitals that are defined as P-DCCHs in this analysis. We obtained the institutional information of the DCCHs from the Center for Cancer Control and Information Services of the National Cancer Center, Japan. The data from each DCCH were submitted to the Ministry of Health, Labor and Welfare of Japan in October 2011, and that of each DCCH has been updated on a regular basis.
We collected the data of all 397 DCCHs, which included the number of medical staff working in radiotherapy departments, such as ROs, medical physicists (MPs), radiotherapy quality managers (RQMs) and radiation therapists (RTs), the number of linear accelerators, the number of patients who were treated with radiotherapy per year and radiotherapy use for each disease site in detail (e.g. SBRT, IMRT and brachytherapy) as of November 2012. We calculated the proportion of implementation of the advanced radiation techniques for IMRT for head and neck and prostate cancers, and SBRT for lung cancer according to each kind of DCCH. The proportion of implementation means that of institutions which have potential availability of advanced radiation technologies.
Differences between the two sample medians for continuous variables were analyzed using Pearson's chi-squared test. P values of ,0.05 were considered significant. Multivariate analyses were performed using the logistic regression model. Statistical analyses were performed using JMP version 10.0.0 (SAS Institute, Inc.).
RESULTS

INSTITUTE'S QUALIFICATION FOR ADVANCED RADIOTHERAPY TECHNOLOGIES
Japanese health insurance providers cover the cost of SBRT and IMRT only at hospitals which satisfy the institute's qualification including the number and year of experience of fulltime ROs, appropriate treatment machine and planning systems for these advanced radiotherapy techniques and adequate radiotherapy quality control (QC) system. The institute's qualification for IMRT includes (i) two or more full-time ROs, (ii) at least one of them who has over 5 years experience in radiotherapy, (iii) at least one full-time RT who has over 5 years experience in radiotherapy, (iv) appropriate treatment machine and inverse planning systems for IMRT and (v) adequate radiotherapy QC system. The institute's qualification for stereotactic radiotherapy (SRT) includes (i) at least one full-time RO, (ii) appropriate treatment machine for SRT and (iii) appropriate treatment system for SRT. Thirty P-DCCHs (57%) satisfy the institute's qualification for IMRT, and 76 R-DCCHs (22%) satisfy it (P , 0.001). Forty-seven P-DCCHs (89%) with institute's qualification for SRT, and 175 R-DCCHs (51%) satisfy it (P , 0.001).
IMRT FOR HEAD AND NECK CANCERS
In November 2012, only 53% P-DCCHs and 16% R-DCCHs had been using IMRT for head and neck cancers. The results of our univariate analyses of the implementation of IMRT for head and neck cancers, which included the number of linear accelerators, those of medical staff such as ROs, RTs, RQMs and MPs are shown in Table 1 according to the types of DCCH. We analyzed the 30 P-DCCHs which satisfy the institute's qualification for IMRT, and the multivariate analysis including the five factors listed above revealed that there was no factor associated with IMRT implementation for head and neck cancers ( Table 2) . But there was a trend to correlate the number of ROs with IMRT implementation for head and neck cancers (P ¼ 0.08). We analyzed the 76 R-DCCHs with institute's qualification for IMRT, and the multivariate analysis revealed that there was no factor associated with IMRT implementation for head and neck cancers ( Table 2) .
IMRT FOR PROSTATE CANCER
Only 62% P-DCCHs and 23% R-DCCHs had been using IMRT for prostate cancer. The results of the univariate analysis of IMRT for prostate cancer, which included the five factors listed above, are shown in Table 1 according to the types of DCCHs. We analyzed the 30 P-DCCHs with institute's qualification for IMRT, and the multivariate analysis revealed that the number of ROs (P ¼ 0.01) and that of RTs (P ¼ 0.003) were significantly correlated with IMRT implementation for prostate cancers (Table 2 ). Our multivariate analysis of the 76 R-DCCHs with institute's qualification for IMRT revealed no factor associated with IMRT implementation for prostate cancer.
SBRT FOR LUNG CANCER
At the time of our survey, 74% P-DCCHs and 40% R-DCCHs were using SBRT for lung cancer. The results of the univariate analysis of SBRT for lung cancer are shown according to the types of DCCH (Table 1) . We analyzed the 47 P-DCCHs with institute's qualification for SBRT, and the multivariate analysis including the five factors listed above revealed that the number of ROs was significantly correlated with SBRT implementation for lung cancers (P ¼ 0.02) ( Table 2 ). There was a trend to correlate the number of MPs with SBRT implementation for lung cancers (P ¼ 0.07). We analyzed the 175 R-DCCHs with institute's qualification for SBRT, and the multivariate analysis revealed that there was no factor associated with SBRT implementation for lung cancers at these hospitals.
QUALITY ASSURANCE/QUALITY CONTROL (QA/QC) SYSTEM
The freedom of information act data from the Center for Cancer Control and Information Services showed that only nine P-DCCHs (17%) and 46 R-DCCHs (13%) had a radiotherapy quality assurance (QA) committee, and the output dose of linear accelerators was evaluated by a third party in only 26 P-DCCHs (49%) and 150 R-DCCHs (44%).
DISCUSSION
IMRT reduces the dose to the organ at risk while maintaining good coverage of the target (1), and it has rapidly become a 
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IMRT/SBRT in designated cancer care hospitals widely adopted treatment approach among American ROs. This increase in the use of IMRT could be attributed in part to the fact that multiple investigators have reported dosimetric advantages and consequent improvement in the xerostomia rate, rectal toxicity rate and quality of life measures following the use of IMRT (3, 7, 8) .
In the UK, Mayles et al. performed a survey and found that in 2008 only 6.7% of the patients with head and neck cancers and 7.5% of the patients with prostate cancers received IMRT (9) . Their survey included questions about the reasons for not using IMRT, and the respondents' answer showed that the main reasons for the lack of progress in using IMRT in the UK were the inadequate availability of MPs, the lack of funding, the lack of equipment and the inadequate availability of ROs. The present IMRT situations in the UK is thus similar in some ways to those in Japan, with the need for more ROs and other types of medical staff in the department of radiation oncology for the establishment of a training system for IMRT. In particular, in Japan's R-DCCHs, the proportion of implementation of IMRT is very small, and the insufficient number of medical staff working in radiotherapy departments and the small number of R-DCCHs with institute's qualification for IMRT have been serious problems. The high fee for IMRT might lead to its prevalence, but it causes the unnecessary implementation for the patients who do not receive its benefit. The appropriate indication of advanced radiation technologies should be established.
In contrast, in the USA, the rapid adoption of IMRT in the wider clinical practice has shown that there is great variability in IMRT delivery such as incorrect contouring and the various margins, dose and techniques used for anal cancer and other malignancies (10, 11) . The establishment of adequate IMRT requires not only sufficient number of operating staff, but also the preparation of IMRT training programs for each type of operating staff in the radiation department (12). Routsis et al. (13) proposed that the reason for the slow adoption of IMRT in the UK is associated with insufficient understanding and skills concerning IMRT among the operating staff. The Radiotherapy Development Board in the UK has begun education and training programs for IMRT for each type of medical staff in the radiation department. Our survey revealed that the proportion of IMRT for head and neck cancers in Japan was small. Especially, head and neck anatomy is complex, and the physical examination, image evaluation and radiation treatment of this region are technically demanding. Rosenthal et al. (14) emphasized the importance of the patient examination in the clinical quality assurance of head and neck radiotherapy, and they observed that a co-examination by a second head and neck cancer specialist-typically a RO or a head and neck surgeon-improved the accuracy of the radiation plan, including the target volume. The adequate IMRT for head and neck cancers requires not only a sufficient system of radiation oncology department, but also experienced head and neck surgeon's team. SBRT uses an advanced technology to deliver a potent ablative high dose of radiation to deep-seated tumors, in a limited number of fractions to extracranial targets such as lung, liver, spine, pancreas, kidney and prostate (15) . But the Japanese health insurance providers cover the cost of SBRT for only primary lung cancer, metastatic lung tumor, primary hepatic cancer, metastatic liver tumor and arteriovenous malformation of spinal cord. Accurate SBRT requires an immobilization system to prevent patient movement, accurate repositioning in each treatment, rigorous accounting of organ motion, stereotactic registration in the treatment system of the tumor targets and the normal-tissue avoidance structures and ablative high doses delivered to the patient with sub-centimeter accuracy. The implementation of accurate SBRT also requires sufficient understanding and skills among the operative staff, including ROs, MPs, RTs and RQMs. Pan et al. (6) performed an online SBRT survey for the American Society for Radiation Oncology members, and the results revealed that ROs in academic centers were more likely to cite clinical research as a motivation for SBRT adoption (59 versus 18%; P , 0.0001) compared with those in private practice. The other common reasons for adopting SBRT were to allow the delivery of doses higher than conventional radiation doses and retreatment. SBRT for small-sized lung cancer seems to be one of the optional treatments for medically inoperative patients (2) . The rapidly aging society of Japan is a serious problem, and SBRT may be an important treatment option for elderly patients with comorbidities.
The UK guidelines emphasized the importance of QA/QC systems in the safe delivery of advanced radiotherapy technologies (12) . In Japan, only 15% of the DCCHs have radiotherapy QA committees. Within each hospital, QA committees should hold regular meetings not only to manage the quality of radiotherapy, but also to maintain the safety of patients and working staff in the department of radiation oncology at all times (16 -19) . The QA committee should make concrete QA/QC manuals, work flow of plans for radiotherapy and educational programs for radiotherapy staff (11, 17, 18, 20) . The linear accelerator output dose was evaluated by a trusted third party in less than one-half of the DCCHs in Japan. The International Atomic Energy Agency and World Health Organization have measured the output dose of linear accelerators, and .60% of institutions worldwide which have linear accelerators are evaluated by these trusted third-party organizations (18). From an international viewpoint, the QA/QC systems in Japanese hospitals are insufficient. An adequate QA/QC system should be established in each hospital for the use of advanced radiotherapy technologies.
Our survey has some limitations. The patient's choice of hospitals is associated with high-volume hospitals and implementation of advanced radiation technologies, and the use of advanced radiation technologies might be based on the sufficient manpower in the department of radiation oncology, physicians' abilities and the radiation treatment systems, including high-quality linear accelerator and radiation planning machine, which are appropriate for the advanced technologies, and QA/QC systems. Our survey mainly focused on the number of medical staff in the department of radiation oncology. We could not ascertain the subspecialties, license and years of experience of the medical staff, or the quality of the linear accelerators and radiation planning systems. Surveys including the year of experience of the medical staff and the details of the radiotherapy treatment systems will be helpful to clarify the problems regarding the advanced radiation technologies in Japan. We could not analyze the role of nurse in the radiotherapy department because of lack of information. A part of P-DCCH and R-DCCHs seem to have submitted wrong data to the Ministry of Health, Labor and Welfare of Japan (e.g. number of full-time ROs) in error. There are some discrepancies between the number of hospitals with the institute's qualification for advanced radiotherapy technologies and those of hospitals which used these techniques. But we could not check all of them because of large volume of data. We performed analyses using the original data.
